TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo December 16, 2020 Kouji Eguchi Chief Executive Officer Medirom Healthcare Technologies Inc. 2-3-1 Daiba, Minato-ku Tokyo 135-0091, Japan Re: Medirom Healthcare Technologies Inc. Amendment No. 2 to Registration Statement on Form F-1 Filed December 11, 2020 File No. 333-250762 Dear Mr. Eguchi: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our December 9, 2020 letter. Amendment No. 2 to Form F-1 Filed December 11, 2020 Capitalization, page 43 1. Please provide your calculation of the pro forma cash and cash equivalents balance as of June 30, 2020. Dilution, page 44 2. Please provide us with your calculation of $12,812 thousand pro forma net intangible book value as of June 30, 2020. Kouji Eguchi FirstName LastNameKouji EguchiInc. Medirom Healthcare Technologies Comapany16, December NameMedirom 2020 Healthcare Technologies Inc. December Page 2 16, 2020 Page 2 FirstName LastName General 3. Please revise the registration statement cover page, prospectus cover page, and disclosure throughout the prospectus to identify the aggregate number of shares that you are registering in connection with the offering. You may contact Suying Li at (202) 551-3335 or Linda Cvrkel at (202) 551-3813 if you have questions regarding comments on the financial statements and related matters. Please contact Nicholas Lamparski at (202) 551-4695 or Lilyanna Peyser at (202) 551-3222 with any other questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Barbara A. Jones